These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33024022)

  • 41. The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
    de Lemos LLP; Guerra Júnior AA; Santos M; Magliano C; Diniz I; Souza K; Pereira RG; Alvares J; Godman B; Bennie M; Zimmermann IR; Dos Santos VCC; Pretramale CA; Acurcio FA
    Pharmacoeconomics; 2018 Feb; 36(2):161-173. PubMed ID: 29139001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
    Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
    Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
    Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
    Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR
    PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alemtuzumab for multiple sclerosis: who and when to treat?
    Sprenger T; Kappos L
    Lancet; 2012 Nov; 380(9856):1795-7. PubMed ID: 23128041
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
    Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
    Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
    Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    Foong YC; Merlo D; Gresle M; Buzzard K; Zhong M; Yeh WZ; Jokubaitis V; Monif M; Skibina O; Ozakbas S; Patti F; Grammond P; Amato MP; Kalincik T; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Lechner Scott J; Boz C; Sa MJ; Butzkueven H; van der Walt A; Zhu C;
    J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):767-774. PubMed ID: 38453478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
    J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.